Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: Effectiveness of ustekinumab.

Benzaquen M, Monnier J, Beaussault Y, Rouby F, Berbis P.

Australas J Dermatol. 2017 Nov;58(4):e270-e271. doi: 10.1111/ajd.12545. Epub 2017 Jun 28. No abstract available.

PMID:
28660635
2.

Treatment of severe recalcitrant pyoderma gangrenosum with ustekinumab.

Low ZM, Mar A.

Australas J Dermatol. 2018 May;59(2):131-134. doi: 10.1111/ajd.12744. Epub 2017 Dec 4.

PMID:
29205260
3.

Worsening of Psoriatic Arthritis After Ustekinumab Treatment.

Onsun N, Yalcin B, Sallahoglu K, Rezvani A.

Am J Ther. 2018 May/Jun;25(3):e381-e382. doi: 10.1097/MJT.0000000000000546. No abstract available.

PMID:
29189317
4.

Successful treatment of refractory pyoderma gangrenosum with ustekinumab only after excision of renal cell carcinoma.

Cosgarea I, Lovric Z, Körber A, Dissemond J.

Int Wound J. 2016 Oct;13(5):1041-2. doi: 10.1111/iwj.12377. Epub 2014 Oct 8. No abstract available.

PMID:
25294697
5.

Successful treatment with ustekinumab and vacuum-assisted closure therapy in recalcitrant myelodysplastic syndrome-associated pyoderma gangrenosum: case report and literature review.

Nieto D, Sendagorta E, Rueda JM, Herranz P.

Clin Exp Dermatol. 2019 Jan;44(1):116-119. doi: 10.1111/ced.13679. Epub 2018 May 30. No abstract available.

PMID:
29851121
6.

Severe dilated cardiomyopathy induced by adalimumab and ustekinumab.

Membrillo de Novales FJ, Ávila Jiménez A, Merino Meléndez L, Torres León J, López Soberón E, Fe Marqués A, Pérez Mochales JF.

J Clin Rheumatol. 2015 Apr;21(3):171-3. doi: 10.1097/RHU.0000000000000237. No abstract available.

PMID:
25807103
7.

Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.

Mugheddu C, Atzori L, Del Piano M, Lappi A, Pau M, Murgia S, Zucca I, Rongioletti F.

Dermatol Ther. 2017 Sep;30(5). doi: 10.1111/dth.12527. Epub 2017 Aug 18.

PMID:
28833973
8.

Arthritis possibly induced and exacerbated by a tumour necrosis factor antagonist in a patient with psoriasis vulgaris.

Takahashi T, Asano Y, Shibata S, Nakamura K, Nakao M, Shida R, Mitsui A, Araki M, Watanabe R, Fujita H, Tada Y, Sato S.

Br J Dermatol. 2015;172(5):1458-60. doi: 10.1111/bjd.13587. Epub 2015 Mar 18. No abstract available.

PMID:
25565011
9.

Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: A multicenter retrospective study.

de Risi-Pugliese T, Seksik P, Bouaziz JD, Chasset F, Moguelet P, Gornet JM, Bourrier A, Amiot A, Beaugerie L, Francès C, Guégan S; Ustekinumab–Crohn's Disease–Neutrophilic Dermatosis Study Group.

J Am Acad Dermatol. 2019 Mar;80(3):781-784. doi: 10.1016/j.jaad.2018.06.065. Epub 2018 Jul 10. No abstract available.

PMID:
30003991
10.

Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab.

Čarija A, Ivić I, Marasović-Krstulović D, Puizina-Ivić N.

Rheumatology (Oxford). 2015 Nov;54(11):2114-6. doi: 10.1093/rheumatology/kev263. Epub 2015 Aug 4. Review. No abstract available.

PMID:
26242857
11.

The safety of ustekinumab for the treatment of psoriatic arthritis.

López-Ferrer A, Laiz A, Puig L.

Expert Opin Drug Saf. 2017 Jun;16(6):733-742. doi: 10.1080/14740338.2017.1323864. Epub 2017 May 9. Review.

PMID:
28441904
12.

A review of ustekinumab in the treatment of psoriatic arthritis.

Roberts J, O'Rielly DD, Rahman P.

Immunotherapy. 2018 Apr;10(5):361-372. doi: 10.2217/imt-2017-0149. Epub 2018 Feb 14. Review.

PMID:
29439608
13.

Treatment with ustekinumab in a Spanish cohort of patients with psoriasis and psoriatic arthritis in daily clinical practice.

Almirall M, Rodriguez J, Mateo L, Carrascosa JM, Notario J, Gallardo F.

Clin Rheumatol. 2017 Feb;36(2):439-443. doi: 10.1007/s10067-016-3464-x. Epub 2016 Nov 5.

PMID:
27817126
14.

Is ustekinumab effective for psoriatic arthritis with insufficient response to initial treatment?

Venegas-Iribarren S, Andino-Navarrete R.

Medwave. 2018 Mar 8;18(2):e7174. doi: 10.5867/medwave.2018.02.7173. Spanish, English.

PMID:
29522505
15.

[Efficacy and safety of ustekinumab in psoriatic arthritis after anti-TNFα failure in routine practice].

Michel M, Reguiai Z, Fauconier M, Brochot P, Eschard JP, Salmon JH.

Therapie. 2016 Jun;71(3):281-6. doi: 10.1016/j.therap.2015.07.001. Epub 2016 Apr 1. French.

PMID:
27235651
16.

High-dose ustekinumab for the treatment of severe, recalcitrant pyoderma gangrenosum.

Greb JE, Gottlieb AB, Goldminz AM.

Dermatol Ther. 2016 Nov;29(6):482-483. doi: 10.1111/dth.12387. Epub 2016 Aug 9. No abstract available.

PMID:
27502191
17.

Non-psoriatic dermatologic uses of monoclonal antibody therapy.

Sockolov ME, Alikhan A, Zargari O.

J Dermatolog Treat. 2009;20(6):319-27. doi: 10.3109/09546630902936778. Review.

PMID:
19954387
18.

A Case Series of Patients With Psoriasis Exposed to Biologic Therapy During Pregnancy: The BIOBADADERM Register and a Review of the Literature.

Echeverría-García B, Nuño-González A, Dauden E, Vanaclocha F, Torrado R, Belinchón I, Pérez-Zafrilla B; Grupo de estudio BIOBADADERM.

Actas Dermosifiliogr. 2017 Mar;108(2):168-170. doi: 10.1016/j.ad.2016.09.004. Epub 2016 Oct 17. Review. English, Spanish. No abstract available.

PMID:
27765165
19.

Late paradoxical development of pyoderma gangrenosum in a psoriasis patient treated with infliximab.

Vestita M, Guida S, Mazzoccoli S, Loconsole F, Foti C.

Eur J Dermatol. 2015 May-Jun;25(3):272-3. doi: 10.1684/ejd.2015.2526. No abstract available.

PMID:
25786592
20.

Combination of antitumour necrosis factor-α and anti-interleukin-12/23 antibodies in refractory psoriasis and psoriatic arthritis: a long-term case-series observational study.

Gniadecki R, Bang B, Sand C.

Br J Dermatol. 2016 May;174(5):1145-6. doi: 10.1111/bjd.14270. Epub 2016 May 4. No abstract available.

PMID:
26522308

Supplemental Content

Support Center